News & Events
2010 Press Releases
Eidogen-Sertanty Releases iKinasePro - an iPad App in the Cloud
San Diego, CA (April 7, 2010) - Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today the release of iKinasePro, a new mobile application enabling chemical substructure and similarity searching on the iPad while leveraging cloud-based server infrastructure.
iKinasePro provides access into a version of Eidogen-Sertanty's popular Kinase Knowledgebase (KKB) hosted in Amazon's cloud computing environment. Using native iPad functionality, a user can survey the large and growing KKB by target-name, by Kinome-tree taps, and by structure-based searches. Users can register for e-mail alerts to notify them when additional information becomes available on molecules of interest.
iKinasePro introduces new "search-by-tap" functionality that allows a user to explore the world of kinases by tapping through a vast array of kinase-relevant ring structures, or by tapping on subfamilies within the Kinome tree. Users can also issue custom structure searches through finger-drawn substructures.
"We are very excited to bring together two cutting-edge technologies for this application, said Dr. Steven Muskal, CEO of Eidogen-Sertanty. "The iPad is truly a revolutionary device that is expected to change the shape of mobile computing. Coupling these handheld devices with a highly scalable and cost-effective cloud-based server-side compute infrastructure is a match made in heaven."
To see the application in the App store, please see iKinasePro for the iPad.
For more information, please contact:
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit www.eidogen-sertanty.com.